BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun Y, Zhao Y, Zhao X, Lee RJ, Teng L, Zhou C. Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation. Molecules 2017;22:E1724. [PMID: 29027965 DOI: 10.3390/molecules22101724] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Ning L, Liu M, Gou Y, Yang Y, He B, Huang J. Development and application of ribonucleic acid therapy strategies against COVID-19. Int J Biol Sci 2022;18:5070-85. [PMID: 35982905 DOI: 10.7150/ijbs.72706] [Reference Citation Analysis]
2 Mendes BB, Conniot J, Avital A, Yao D, Jiang X, Zhou X, Sharf-Pauker N, Xiao Y, Adir O, Liang H, Shi J, Schroeder A, Conde J. Nanodelivery of nucleic acids. Nat Rev Methods Primers 2022;2:24. [PMID: 35480987 DOI: 10.1038/s43586-022-00104-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
3 Zhao Y, Shu R, Liu J. The development and improvement of ribonucleic acid therapy strategies. Mol Ther Nucleic Acids 2021;26:997-1013. [PMID: 34540356 DOI: 10.1016/j.omtn.2021.09.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Pandey M, Ojha D, Bansal S, Rode AB, Chawla G. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Mol Aspects Med 2021;:101003. [PMID: 34332771 DOI: 10.1016/j.mam.2021.101003] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Ren H, Zhang Z, Zhang W, Feng X, Xu L. Prodrug-type antisense oligonucleotides with enhanced nuclease stability and anti-tumour effects. Eur J Pharm Sci 2021;162:105832. [PMID: 33826934 DOI: 10.1016/j.ejps.2021.105832] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong XB. The growth of siRNA-based therapeutics: Updated clinical studies. Biochem Pharmacol 2021;189:114432. [PMID: 33513339 DOI: 10.1016/j.bcp.2021.114432] [Cited by in Crossref: 13] [Cited by in F6Publishing: 61] [Article Influence: 13.0] [Reference Citation Analysis]
7 Hersh J, Broyles D, Capcha JMC, Dikici E, Shehadeh LA, Daunert S, Deo S. Peptide-Modified Biopolymers for Biomedical Applications. ACS Appl Bio Mater 2021;4:229-51. [PMID: 34250454 DOI: 10.1021/acsabm.0c01145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sajid MI, Moazzam M, Kato S, Yeseom Cho K, Tiwari RK. Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside. Pharmaceuticals (Basel) 2020;13:E294. [PMID: 33036435 DOI: 10.3390/ph13100294] [Cited by in Crossref: 13] [Cited by in F6Publishing: 39] [Article Influence: 6.5] [Reference Citation Analysis]
9 Singh P, Singh A, Shah S, Vataliya J, Mittal A, Chitkara D. RNA Interference Nanotherapeutics for Treatment of Glioblastoma Multiforme. Mol Pharm 2020;17:4040-66. [PMID: 32902291 DOI: 10.1021/acs.molpharmaceut.0c00709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Zhang Y, Ge J. Green nanoparticles for oligonucleotide delivery. Gene Ther 2020;27:535-6. [PMID: 32651567 DOI: 10.1038/s41434-020-0173-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
11 Zhan H, Tu S, Zhang F, Shao A, Lin J. MicroRNAs and Long Non-coding RNAs in c-Met-Regulated Cancers. Front Cell Dev Biol 2020;8:145. [PMID: 32219093 DOI: 10.3389/fcell.2020.00145] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
12 Paganin-gioanni A, Rols M, Teissié J, Golzio M. Cyclin B1 knockdown mediated by clinically approved pulsed electric fields siRNA delivery induces tumor regression in murine melanoma. International Journal of Pharmaceutics 2020;573:118732. [DOI: 10.1016/j.ijpharm.2019.118732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Versteeg L, Almutairi MM, Hotez PJ, Pollet J. Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections. Vaccines (Basel) 2019;7:E122. [PMID: 31547081 DOI: 10.3390/vaccines7040122] [Cited by in Crossref: 14] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
14 Ong W, Pinese C, Chew SY. Scaffold-mediated sequential drug/gene delivery to promote nerve regeneration and remyelination following traumatic nerve injuries. Adv Drug Deliv Rev 2019;149-150:19-48. [PMID: 30910595 DOI: 10.1016/j.addr.2019.03.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
15 Zhao W, Hou X, Vick OG, Dong Y. RNA delivery biomaterials for the treatment of genetic and rare diseases. Biomaterials 2019;217:119291. [PMID: 31255978 DOI: 10.1016/j.biomaterials.2019.119291] [Cited by in Crossref: 14] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
16 Ni WJ, Wu YZ, Ma DH, Leng XM. Noncoding RNAs in Calcific Aortic Valve Disease: A Review of Recent Studies. J Cardiovasc Pharmacol 2018;71:317-23. [PMID: 29734266 DOI: 10.1097/FJC.0000000000000569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
17 Hernández M, Leyva G, Magaña JJ, Guzmán-Vargas A, Felipe C, Lara V, Lima E. New copolymers as hosts of ribosomal RNA. BMC Chem 2019;13:33. [PMID: 31384781 DOI: 10.1186/s13065-019-0555-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhang L, Liao Y, Tang L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res 2019;38:53. [PMID: 30717802 DOI: 10.1186/s13046-019-1059-5] [Cited by in Crossref: 94] [Cited by in F6Publishing: 163] [Article Influence: 31.3] [Reference Citation Analysis]
19 Marafini I, Monteleone G. Inflammatory bowel disease: new therapies from antisense oligonucleotides. Ann Med 2018;50:361-70. [PMID: 29911450 DOI: 10.1080/07853890.2018.1490025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]